Hyponatremia during carbamazepine therapy in patients with intellectual disability.
Low sodium hits 4 in the adults with ID on carbamazepine—order the lab before you see symptoms.
01Research in Context
What this study did
Doctors tracked sodium levels in adults with intellectual disability who lived in group homes.
Half took the seizure drug carbamazepine. The rest did not.
Blood tests showed who got low sodium, a problem called hyponatremia.
What they found
Four out of ten on carbamazepine had low sodium. Only one in ten controls did.
Higher daily dose and higher blood level of the drug raised the risk.
Many people felt fine, so the drop was easy to miss without a lab test.
How this fits with other research
Hilton et al. (2010) say use a scale like MEDS or DISCUS to watch for side effects. Allen et al. (2001) prove you also need a simple blood test, because low sodium hides from checklists.
Congiu et al. (2010) show more drug classes mean more side effects. Their study and this one both used group comparisons in the same population, backing the rule: count and measure every drug you give.
Ingham et al. (1992) warn that rare med events can kill. Low sodium sounds mild, but seizures and coma can follow, so the risk is just as real.
Why it matters
If a client takes carbamazepine, add serum sodium to the quarterly lab slip. No behavior change is needed to justify the test. Catch the drop early, lower the dose or switch meds, and you prevent a medical crisis that looks like "increased behaviors" but is really a salt problem.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Print the current med list, circle anyone on carbamazepine, and email the nurse to add sodium to the next blood draw.
02At a glance
03Original abstract
Carbamazepine is an anticonvulsant and psychotropic medication commonly used in the treatment of people with intellectual disability (ID). The incidence of hyponatremia during treatment in this population is unclear. The present study aimed to determine the prevalence of hyponatremia during carbamazepine treatment in patients with ID, and to investigate the risk factors and clinical features of this condition. The prevalence of hyponatremia was retrospectively assessed in 53 people receiving carbamazepine (subject group) and 64 people not receiving carbamazepine (control group) who lived in a residential centre for people with ID. The relationship between serum sodium level, sex, age, daily carbamazepine dose and serum carbamazepine levels was examined. The prevalence of the clinical features of hyponatremia was assessed in this population using a checklist. The prevalence of hyponatremia was 41.5% and 9.4% in the subject and control groups, respectively. The mean serum sodium level in the subject group was significantly lower than that in the control group. Hyponatremia correlates significantly with a high daily carbamazepine dose and a high serum carbamazepine level. The checklist of clinical features was not useful in detecting hyponatremia clinically. Hyponatremia is a common occurrence in this population. In the light of the uncertain significance of mild, chronic hyponatremia, the value of routine monitoring of serum electrolytes has yet to be established.
Journal of intellectual disability research : JIDR, 2001 · doi:10.1046/j.1365-2788.2001.00338.x